White House Slams Generic Exclusivity Provisions In User Fee Bill
Executive Summary
Trump administration says generic exclusivity provisions – which have been softened from the original bill – are unpredictable and could decrease competition; and while the White House is displeased with exclusivity, and wants higher user fees, it is not explicitly threatening a veto.
You may also be interested in...
Next User Fee Cycle Should Focus On Policy Improvements, Gottlieb Says
US FDA commissioner wants to focus on new policies that will improve innovation and move beyond incremental process improvements.
FDARA Takes Effect With Under-The-Radar Presidential Signature
Key FDA legislation moves to implementation phase with presidential signature but little fanfare.
FDARA Takes Effect With Under-The-Radar Presidential Signature
Key FDA legislation moves to implementation phase with presidential signature but little fanfare.